Skip to main content
Clinical Trials/NCT06165744
NCT06165744
Completed
Not Applicable

Next Generation Cataract and Vitreoretinal Surgery Study

Alcon Research5 sites in 1 country120 target enrollmentStarted: February 27, 2024Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
120
Locations
5
Primary Endpoint
Percent of 'Yes' Responses to the Binary Question: "Did UNITY VCS Using Vitreoretinal or Combined Surgical Functionality Perform Per the Intended Use as Defined in Protocol Section 5.1?"

Overview

Brief Summary

The purpose of this study is to obtain device-specific safety and performance clinical data to support marketability in Europe and to collect formal user feedback.

Detailed Description

Subjects will attend a screening visit (Day -30 to Day 0), a surgery visit (Day 0), and 4 post-surgical visits (Day 1, Week 1, Month 1, Month 3) for an overall individual duration of approximately 4 months. One eye (study eye) will be treated. This study will be conducted in Australia.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Requires posterior segment surgery in the operating room with or without simultaneous cataract surgery;
  • Clear media except for cataract and vitreous hemorrhage;
  • In simultaneous cataract and vitreoretinal surgery, eligible to undergo primary hydrophobic acrylic intraocular lens (IOL) implantation into the capsular bag;
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • Previous vitrectomy in the operative eye aside from those requiring silicone oil removal;
  • Neovascular or uncontrolled glaucoma;
  • Planned glaucoma or postoperative surgeries during study aside from silicone oil removal;
  • Inadequate pupil dilation (less than 6 millimeters);
  • Other protocol-defined exclusion criteria may apply.

Outcomes

Primary Outcomes

Percent of 'Yes' Responses to the Binary Question: "Did UNITY VCS Using Vitreoretinal or Combined Surgical Functionality Perform Per the Intended Use as Defined in Protocol Section 5.1?"

Time Frame: Day 0

As recorded by the surgeon on a user questionnaire based on Day 0 surgery experience. From Protocol Section 5.1, the intended use for UNITY VCS is to facilitate the management of fluid and gases, as well as removal, grasping, cutting, illumination, and coagulation of ocular materials during ocular surgery. One eye (study eye) contributed data to the analysis. No hypothesis testing was pre-specified for this endpoint.

Secondary Outcomes

  • Mean Total Time in Eye(Day 0 operative, up to surgery completion)
  • Percent of 'Yes' Responses to the Binary Question, "Was Anatomical Success Achieved for Intended Treatment?"(Month 3 Postoperative)
  • Mean Change in Monocular Best Corrected Distance Visual Acuity (BCDVA) From Preoperative to Month 3(Preoperative (Day -30 to 0), Month 3 Postoperative)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (5)

Loading locations...

Similar Trials